You are here: Industry Insights > SARS-CoV-2

News List

COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial worldpharmanews
July 21, 2020
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
Valneva to Provide SARS-CoV-2 Vax Candidate to UK Govt contractpharma
July 21, 2020
Valneva's VLA2001, an inactivated whole virus vaccine candidate against coronavirus is expected to enter clinical studies by the end of 2020.
Common FDA-approved drug may effectively neutralize virus that causes COVID-19 worldpharmanews
July 17, 2020
A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.
Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients worldpharmanews
July 17, 2020
The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) was ...
US researchers say heparin may neutralise Covid-19 virus pharmaceutical-technology
July 17, 2020
Researchers at Rensselaer Polytechnic Institute in the US have said that the commonly available, US Food and Drug Administration (FDA)-approved drug heparin could effectively neutralise SARS-CoV-2, the virus that causes Covid-19.
OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax contractpharma
July 17, 2020
OSE’s research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope-peptide approach.
Study finds fenofibrate may downgrade Covid-19 to common cold level pharmaceutical-technology
July 16, 2020
A study conducted by professor Yaakov Nahmias at Hebrew University in Israel has found that an existing cholesterol drug, fenofibrate, could ‘downgrade’ Covid-19 threat level to that of a common cold.
Researchers find key element in human antibodies against COVID-19 expresspharma
July 15, 2020
The study results can facilitate the design of vaccine agents that can elicit a strong neutralising antibody response, say scientists.
FDA grants Fast Track designation to two COVID-19 vaccines europeanpharmaceuticalreview
July 14, 2020
Two investigational SARS-CoV-2 vaccine candidates, BNT162b1 and BNT162b2, currently in clinical trials have been granted Fast Track designation by the FDA.
Neutralizing antibodies in the battle against COVID-19 worldpharmanews
July 10, 2020
An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page